You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Cell-free protein synthesis (CFPS) devices with high-yield for synthetic biology

    SBC: DASFANH BIOSCIENCES, LLC            Topic: 400

    Project SummaryCell free protein synthesisCFPSis a method of producing proteins outside living cells and has distinct advantages over traditional cell culture based protein productionIt is often difficult to maintain complex environmental condition for cell viability and the subsequent need to develop a downstream process for purification of product in traditional cell based systemsCFPSon the othe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)

    SBC: LUNG THERAPEUTICS INC            Topic: NHLBI

    Abstract Systemic sclerosissclerodermaSScis a chronic connective tissue disease in which lung fibrosis is the most frequent cause of deathSSc and idiopathic pulmonary fibrosis are the two most common disease that falls under the interstitial lung diseasesILDa grouping of devastating diseases in which lung fibrosis leads to progressive shortness of breatha very poor quality of lifeand death within ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Immuno-oncology Strategy for Targeted Cytotoxic Lymphocyte Activation

    SBC: Courier Therapeutics Inc            Topic: 102

    PROJECT SUMMARY ABSTRACT Systemic administration of high dose ILhas been used since thes as an FDA approved immunotherapy for metastatic cancerDespite the fact that up toof patients treated with high dose ILachieve a durablelong term responsethis therapy is rarely used today due to significant life threatening complicationsSuch complications occur due to ILactivation of vascular endotheliumresulti ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Portable Liquid Chromatograph for Point-of-Care Monitoring of Illicit Substances

    SBC: AXCEND LLC            Topic: R41

    Project Summary Abstract Point of carePOCtesting of clinical samples for the presence of illegal substances and their metabolites is important for monitoring substance use disordersemployment screeningand legal matters relating to drug abstinenceTypical immunoassay screening methods suffer from higher false testing rates and do not provide quantitative informationConfirmatory tests that are used f ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Small Molecule Inhibitor Therapeutic Target for Alzheimer's Disease.

    SBC: abSynapTex, LLC            Topic: NIA

    Project SummaryThe objective of our proposed research is to develop a water soluble molecule that can reduce the levels of amyloid betaAand Drpand prevent abnormal interactions between Aand Drpin Alzheimers diseaseADaffected neuronsOur previous AD studies foundincreased production and accumulation of Aand increased expression of Drpandan abnormal interaction between Aand Drpin AD neurons that was ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development and non-clinical GLP testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors.

    SBC: KIROMIC BIOPHARMA INC            Topic: NHLBI

    AtheroSclerotic CardioVascular DiseaseASCVDis caused by inflammation within arteriesWhite blood cells enter the arterial wallsmacrophages become engorged with lipid cholesterol and summon other inflammatory cells to form plaques which ultimately rupture or occlude the arterykilling down stream tissuee gheart attackASCVD remains a major cause of morbidity and mortality of the elderlyCoronary artery ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Dose-ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes

    SBC: RIDGELINE THERAPEUTICS LLC            Topic: NIDDK

    ABSTRACTA staggeringof US adults are obeseSince obesity greatly dysregulates glucose homeostasisalmost all obese individuals suffer from TypediabetesT Dor prediabetesThese diseasesand accompanying comorbid chronic health complicationsare largely responsible for burgeoning US healthcare costsUnfortunatelylife style modification programstypically the first line treatment for obesity linked T Drarely ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Tetracycline Analogs for Alcohol Use Disorder Treatment

    SBC: South Plains Biotechnology, Inc            Topic: 350

    Project Summary Abstract Statement of the problemOnly three pharmacotherapeutic treatments for Alcohol Use DisorderAUDare FDA approved and none are widely usedandltof AUD patientsor show a strong effect to reduce riskyor dependence based drinking in the long termandltsee sustained decreased drinking outcomesUnfortunatelyapproximatelyof the population suffers from AUD and overof all medical morbidi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Making Standing Balance The Fifth Vital Sign in Clinical Settings

    SBC: BERTEC CORP            Topic: NIA

    Falls are a significant source of early morbidity and mortality in the aging populationyet the neurologicalsensoryand motor changes that lead to increased fall risk often escape early identification and interventionVital signs are commonly used in clinical settings to assess the cardiovascular systemblood pressureheart rateimmune systembody temperatureand the respiratory systemrespiratory rateto e ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Spleen Tyrosine Kinase (SYK) negative allosteric modifiers for therapeutic intervention in Alzheimer's disease.

    SBC: ARCHER PHARMACEUTICALS, INC.            Topic: NIA

    Pathological hallmarks of Alzheimerandapos s diseaseADinclude extracellular deposits of Apeptidesintraneuronal aggregates of abnormally phosphorylated tau protein and neuroinflammationMost proposed AD disease modifying therapies have focused on strategies that reduce brain Aamyloid or tau pathological accumulationHoweversuch approaches have been unsuccessful in late stage AD clinical trials and ma ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government